53CLINICAL STUDIES SURVEILLANCE STUDIES
Results Improvement in symptoms occurred in the first week for about half of patients,
34% within 1 3 weeks and 8% in >4weeks; no improvement noted in 4%. In 83% of all cases, therapeutic results were rated as good or very good . In
13%, treatment was rated as satisfactory , while in 4% it was unsuccessful . There was no difference in the results of treatment with the two different oral
forms of the medication. Results appeared slightly better in patients receiving Traumeel® alone ( very
good 48.6%) compared with patients receiving concomitant therapy ( very good 33.7%).
As may be expected, success rates were high in acute conditions rather than chronic conditions, although even in chronic conditions positive therapeutic results were in achieved in the majority of case (Figure 22).
Both oral forms of Traumeel® were well tolerated and no adverse reactions were observed.
Figure 22 Good to very good efficacy of Traumeel®, in %*.
Effi ca
cy o
f T ra
um ee
l® %
Acute conditions Chronic conditions
100
90
80
70
60
50
40
30
20
10
0
Br uis
es (n
=2 39
)
Po st-
op er
at ive
ed em
a ( n=
11 3)
Fro ze
n s ho
uld er
(n =1
24 )
He m
at om
as (n
=1 64
)
De ge
ne ra
tiv e j
oin t d
ise as
es (n
=1 70
)
Di slo
ca tio
ns (n
=7 3)
Bu rsi
tis (n
=2 39
)
Sp ra
ins (n
=1 70
)
Jo int
eff us
ion s (
n= 76
)
Ep ico
nd yli
tis (n
=1 01
)
Po st-
tra um
at ic
ed em
a ( n=
11 3)
Ca rp
al tu
nn el
sy nd
ro m
e ( n=
13 0)
Co nc
us sio
ns (n
=2 5)
St ylo
idi tis
(n =1
0)
Conclusion Both orally administered forms of Traumeel® are suitable for treating acute post- traumatic conditions, inflammatory and inflammation-related symptoms.
